Featured Research

from universities, journals, and other organizations

Elderly diabetics have fewer bouts of hypoglycemia at night with new insulin

Date:
June 25, 2012
Source:
Endocrine Society
Summary:
A new variety of long-lasting insulin, called insulin degludec, lowers the risk of nighttime low blood sugar in elderly diabetic adults compared with insulin glargine, a systematic review of diabetes studies has found.

A new variety of long-lasting insulin, called insulin degludec, lowers the risk of nighttime low blood sugar in elderly diabetic adults compared with insulin glargine, a systematic review of diabetes studies has found.

The meta-analysis of phase 3 clinical trials were presented Monday at The Endocrine Society's 94th Annual Meeting in Houston.

"Insulin degludec is a well-tolerated and appropriate therapy for elderly patients with diabetes, who are particularly vulnerable to low blood glucose levels," said the study's lead author Christopher Sorli, MD, chairman of the Department of Diabetes, Endocrinology and Metabolism at Billings Clinic in Billings, Mont.

"Compared with insulin glargine, insulin degludec may offer considerable benefits by reducing the major side effect of insulin therapy, hypoglycemia," Sorli said.

Hypoglycemia, or low blood sugar, occurs often in elderly diabetic patients, especially at night when they are asleep and unable to try to reverse it.

Sorli and the other researchers evaluated the rates of hypoglycemia in 915 patients ages 65 and older who had either Type 1 or Type 2 diabetes. The patients were among more than 4,300 diabetic individuals who participated in one of seven clinical trials that compared insulin degludec with a commercially available insulin (glargine). Insulin degludec is a basal, or long-lasting, injectable insulin that is awaiting approval by the U.S. Food and Drug Administration, according to its manufacturer, Denmark-headquartered Novo Nordisk, which funded this study.

Study participants received treatment once a day for either 26 weeks or 52 weeks. Most patients (632) randomly received insulin degludec, and the other 283 patients randomly received insulin glargine.

Hypoglycemia was defined as a plasma glucose, or blood sugar, level less than 56 milligrams per deciliter or a severe hypoglycemic episode requiring assistance. The rate of hypoglycemia occurring at night was significantly -- 35 percent -- lower in the elderly patients treated with degludec than in those treated with glargine, Sorli said.

In addition, the number of all hypoglycemic episodes was lower in the degludec-treated group than in the glargine-treated group, but this difference was not statistically significant, the investigators reported.

These results in older adults are consistent with previously reported results from the overall adult patient population of these clinical trials, said Sorli, who disclosed that he is a member of Novo Nordisk's speakers bureau and advisory board.

Both insulin degludec and insulin glargine are insulin analogs, which are insulins with modifications to their molecular structures for the purpose of ensuring better therapeutic results. These modifications alter the drug's properties, for example, giving a longer duration of action, which may enable less frequent dosing, Sorli said.


Story Source:

The above story is based on materials provided by Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

Endocrine Society. "Elderly diabetics have fewer bouts of hypoglycemia at night with new insulin." ScienceDaily. ScienceDaily, 25 June 2012. <www.sciencedaily.com/releases/2012/06/120625152352.htm>.
Endocrine Society. (2012, June 25). Elderly diabetics have fewer bouts of hypoglycemia at night with new insulin. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2012/06/120625152352.htm
Endocrine Society. "Elderly diabetics have fewer bouts of hypoglycemia at night with new insulin." ScienceDaily. www.sciencedaily.com/releases/2012/06/120625152352.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins